Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients

Sleep Disorder Clinical Trial

Official title:

Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients With Qi-Yin Deficiency Syndrome During Chemotherapy: a Multicenter, Randomized, Prospective, Real-world Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04641819
• Other study ID #: ESPRESSO
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: April 27, 2021
• Est. completion date: June 30, 2024

Study information

• Verified date: May 2024
• Source: ShuGuang Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a nationwide, multicenter, randomized, prospective, real-world study. The purpose of this study is to evaluate the effect and safety of Yangzheng Compound Mixture in the treatment of sleep disorder in cancer patients with Qi-Yin deficiency syndrome during chemotherapy.

Description:

Sleep disturbance is one of the most common symptoms in cancer patients, the morbidity is about 60%. Drugs commonly used to treat sleep disorders include benzodiazepines, hypnotic antidepressants and melatonin receptors agonists. The short-term efficacy of these drugs has been proven in many clinical trials, but long-term medications bear the risk of adverse reactions and addiction. Yangzheng Compound Mixture is an extract of several traditional Chinese medicines, used as a basic prescription for cancer therapy, especially for patients who received chemotherapy with Qi-Yin deficiency syndrome, which often lead to sleep disturbance, fatigue and anorexia. According to some clinical and basic studies, Yangzheng Compound Mixture also has antitumor and immunomodulatory effects. In this study, about 10 research centers will participate. We planned to enroll 1526 cancer patients (1144 cases in the observation group and 382 cases in the control group) with Qi-Yin deficiency Syndrome and sleep disorders during the period of receiving chemotherapy or combination of chemotherapy. The dynamic random method was adopted in this study, participants will be randomly divided into the experimental group (Yangzheng Compound Mixture plus conventional treatment) and control group (conventional treatment only), all of them will be interviewed once every 3 weeks until the end of the study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1127
• Est. completion date: June 30, 2024
• Est. primary completion date: September 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18;
• Histologically or cytologically confirmed as malignant tumor;
• Receiving chemotherapy or a combination of chemotherapy;
• The syndrome differentiation of traditional Chinese medicine is the Qi-yin deficiency syndrome;
• Sleep disorders were diagnosed by investigators and the Pittsburgh Sleep Quality Index (PSQI) score was = 8;
• The date of diagnosis of sleep disorder is later than the date of the first diagnosis of cancer. Or patients with sleep disorders for a long time receiving regular treatment,sleep disorders aggravated after cancer diagnosis or chemotherapy;
• Pain has been controlled well [patients were being treated with analgesics regularly,numerical rating scale(NRS) score = 3];
• The participant must be able to read and express themselves clearly, can communicate with investigators and cooperate in completing the questionnaire;
• Participants voluntarily join the study with good compliance, and are willing to sign a written informed consent document;
• Survival period will be longer than 6 months.

Exclusion Criteria:

• Pregnant or lactating women;
• Allergic to Yangzheng Compound Mixture;
• Previous diagnosis of sleep apnea;
• The laboratory test value of liver and renal function is more than 2.5 times the upper limit of normal value;
• Symptoms of brain metastasis due to malignant tumor has not been effectively controlled;
• Participating in other drug clinical trials which did not allow to participate in this study;
• Refused to cooperate with follow-up;
• The researchers did not consider it appropriate for the patients to participate in this study for other reasons.

Related Conditions & MeSH terms

• Carcinoma
• Parasomnias
• Sleep Disorder
• Sleep Wake Disorders

Intervention

Drug:
• Yangzheng Compound Mixture
At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance. Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions.

Other:
• Conventional Treatment
Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.

Locations

Country	Name	City	State
China	The Second Affiliated Hospital of Hunan University of Chinese Medicine	Changsha	Hunan
China	Chongqing University Cancer Hospital	Chongqing	Chongqing
China	First Affiliated Hospital, Heilongjiang University of Chinese Medicine	Ha'erbin	Heilongjiang
China	Cancer Hospital of The University of Chinese Academy of Sciences	Hangzhou	Zhejiang
China	Jiamusi Cancer Hospital	Jiamusi	Heilongjiang
China	The Third Affiliated Hospital of Shandong First Medical University	Jinan	Shandong
China	Shuguang Hospital Affiliated with Shanghai University of TCM	Shanghai	Shanghai
China	Zhongshan Hospital	Shanghai	Shanghai
China	Affiliated Hospital of Shanxi University of Chinese Medicine	Xianyang	Shanxi
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (3)

Lead Sponsor	Collaborator
ShuGuang Hospital	LinkDoc Technology (Beijing) Co. Ltd., Shaanxi Buchang Pharmaceutical Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Proportion of leukocyte-increasing drugs used	Proportion of participates used leukocyte-increasing medication during the treatment period	Up to 18 weeks since the start of treatment
Primary	Best effective rate for sleep disorder treatment	Proportion of participants with a minimum PSQI score < 8 during the treatment period.	Measurement was taken at week 6.
Primary	Effective rate for sleep disorder treatment	Proportion of participants with PSQI score < 8 after the end of the different treatment courses.	Measurement was taken at week 6.
Primary	Improvement rate for sleep disorder treatment	Proportion of participates whose PSQI score decreased during treatment compared with the baseline.	Measurement was taken at week 6.
Primary	Change of PSQI score compared with baseline	The PSQI score difference between the end of different treatment courses and baseline.	Baseline and week 6.
Primary	Score of Pittsburgh Sleep Quality Index (PSQI), Sleep duration, Sleep efficiency, Subjective sleep quality, Sleep latency.	The outcomes were evaluated using the PSQI scale.; Sleep duration: response to question 4; Sleep efficiency= (hours slept/ hours in bed) * 100%; Hours slept: response to question 4; Hours in bed: calculated from responses to questions 1 and 3; Subjective sleep quality: response to question 9; Sleep latency: response to question 2.	Measurement was taken at week 6.
Primary	Incidence and severity of AE or SAE	AE: Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.; SAE: A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.	Start of treatment until 30 days after the last day of the sleep disorder treatment
Primary	Incidence and severity of ADR or SADR	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. A SADR is a serious ADR according to the above criteria of SAE.	Start of treatment until 30 days after the last day of the sleep disorder treatment
Secondary	Use frequency of hypnotic agents	Response to question 6 of the PSQI scale.	Up to 18 weeks since the start of treatment
Secondary	Appetite	Appetite was evaluated by using the Cancer Appetite and Symptom Questionnaire(CASQ).	Up to 18 weeks since the start of treatment
Secondary	Fatigue	Fatigue was evaluated by using the Brief Fatigue Inventory(BFI).	Up to 18 weeks since the start of treatment
Secondary	Quality of life (QOL)	Quality of Life (QOL) was measured by using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30).	Up to 18 weeks since the start of treatment
Secondary	Traditional Chinese Medical symptoms scale	Traditional Chinese Medical (TCM) symptoms were measured from these six aspects: weakness, shortness of breath, palpitations, deficiency-heat and vexation, dry mouth, sweat. The minimum score is 0 and the maximum value is 18. Higher scores of TCM scale means a worse outcome.	Up to 18 weeks since the start of treatment